25 May 2013
Keywords: b-ms, gilead, set, up, jv, market, triple
Article | 10 January 2005
US firms Bristol-Myers Squibb and Gilead Sciences have announced details of a joint venture to develop and commercialize the fixed-dose
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 January 2005
24 May 2013
© 2013 thepharmaletter.com